pS2—A new cytosolic protein recognized by monoclonal antibodies as a marker of hormone sensitivity in breast cancer
| Autor: | Francesco Schittulli, Ines Abbate, M. Correale, M. De Lena, M. D. Musci, Annamaria Catino, A. Paradiso, T. Tedone, G. Gargano, C. D. Dragone |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
medicine.medical_specialty medicine.drug_class medicine.medical_treatment Mammary gland Biophysics Breast Neoplasms Biology Monoclonal antibody Biochemistry Steroid Cytosol Breast cancer Internal medicine medicine Humans skin and connective tissue diseases Receptor Aged Aged 80 and over Immunoradiometric assay Tumor Suppressor Proteins Carcinoma Antibodies Monoclonal Proteins Estrogens Cell Biology General Medicine Middle Aged Prognosis medicine.disease Neoplasm Proteins medicine.anatomical_structure Endocrinology Receptors Estrogen Estrogen Female Immunoradiometric Assay Trefoil Factor-1 Multiple Chemical Sensitivity Receptors Progesterone Biomarkers hormones hormone substitutes and hormone antagonists |
| Zdroj: | Cell Biophysics. 22:101-110 |
| ISSN: | 1559-0283 0163-4992 |
| DOI: | 10.1007/bf03033869 |
| Popis: | Using a new immunoradiometric assay (ELSA pS2 Cis-France), a total of 200 cytosols obtained from primary breast tumors were examined for pS2 content, which is an estrogen-regulated protein actually studied as a marker of hormone sensitivity and favorable prognostic factor in breast cancer. In our patient group, the median pS2 value corresponding to 5.3 ng/mg of cytosolic proteins was used as cutoff. pS2 content was not related to menopause status, tumor size, or nodal involvement, whereas a positive correlation was found between pS2 and ER/PgR status. Moreover, the association of pS2 with steroid receptors seems to identify subgroups of patients better than ER/PgR alone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink